stockrowSolventum Corporation
SOLV Healthcare Medical Instruments & Supplies
Solventum Corporation’s revenue for fiscal 2025 (year ended December 2025) was $8.3 billion, up 0.86% from fiscal 2024.
- Revenue
- −7.01%
- EPS
- −101.0%
- Free cash flow
- +561.9%
- Total debt
- −90.1%
Quarter to September 2026, against a year earlier
Follow SOLV
Alert me
Solventum Corporation (SOLV) EV/EBITDA
As of 6 November 2026, Solventum Corporation (SOLV) trades at a EV/EBITDA of 7.9×. Over the past ten years it has ranged from 5.2× (March 2024) to 16.1× (July 2025); the current reading is higher than 46% of that period. That is below the Medical Instruments & Supplies industry median of 14.7× and below the Healthcare sector median of 8.5×.
EV/EBITDA, daily
Embed this chart
Annual newest first
| Period | EV/EBITDA | Change |
|---|---|---|
| FY2025 | 6.8× | (42.44%) |
| FY2024 | 11.7× | 94.29% |
| FY2023 | 6.0× | 0.00% |
| FY2022 | 6.0× | — |
Quarterly newest first
| Period | EV/EBITDA | Change |
|---|---|---|
| Sep 2026 | 7.7× | 9.26% |
| Jun 2026 | 7.1× | 14.04% |
| Mar 2026 | 6.2× | (8.55%) |
| Dec 2025 | 6.8× | 12.45% |
| 11 more quarters | Free account |
Against its own ten years
EV/EBITDA against peers
| Company | EV/EBITDA |
|---|---|
| SOLV Solventum Corporation | 7.9× |
| ALGN Align Technology, Inc. compare | 12.3× |
| ATR AptarGroup, Inc. compare | 13.0× |
| BAX Baxter International Inc. compare | 13.2× |
| BLCO Bausch + Lomb Corporation compare | 14.6× |
| AVTR Avantor, Inc. compare | 15.0× |
| COO The Cooper Companies, Inc. compare | 15.5× |
| WST West Pharmaceutical Services, Inc. compare | 28.8× |
| RGEN Repligen Corporation compare | 62.0× |
| Medical Instruments & Supplies industry median | 14.7× |
| Healthcare sector median | 8.5× |
| Market median | 10.9× |
What EV/EBITDA is
Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)
More on SOLV
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement